Brief: Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)
13/06/2026 12:38
BRIEF-Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z) June 13 (Reuters) - Intellia Therapeutics Inc NTLA.O:
INTELLIA THERAPEUTICS REPORTS ADDITIONAL POSITIVE PHASE 3 RESULTS FOR LONVOGURAN ZICLUMERAN (LONVO-Z) IN PATIENTS WITH HEREDITARY ANGIOEDEMA
INTELLIA THERAPEUTICS - INITIATES ROLLING BLA SUBMISSION FOR LONVO-Z; U.S. LAUNCH EXPECTED FIRST HALF 2027
INTELLIA THERAPEUTICS - HALEO MET ITS PRIMARY ENDPOINT WITH AN 87% REDUCTION (P<0.0001) IN MEAN MONTHLY ATTACKS IN LONVO-Z ARM
Source text: ID:nGNX8FrKfq
Further company coverage: NTLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)